On April 10, 2024, BioVaxys Technology Corp. and SpayVac-for-Wildlife, Inc. have announced their collaboration in the field testing of innovative single-injection, long-lasting immuno-contraceptive vaccines for farmed rainbow trout. This venture utilizes a liposome-based antigen delivery platform technology, licensed from BioVaxys, which has already shown effective and sustained immune responses in various species.

The initiative addresses significant challenges within the commercial aquaculture industry, such as the reduced muscle growth in female fish due to energy diversion to egg production and the ecological risks posed by farm-raised fish that escape and breed with wild populations. By developing reproductively contracepted or sterile fish, these issues can be managed more effectively.

Field trials for this research began this spring in the Pacific Northwest, marking a new direction for SpayVac, which has historically focused on wildlife population management. Dr. Bechert, Vice President of Research and Development at SpayVac-for-Wildlife, expressed excitement over this new application of their technology.

Looking ahead, SpayVac plans to commercialize similar fertility control vaccines for other animals, such as deer and horses, utilizing the same patented technology. James Passin, CEO of BioVaxys, highlighted the promising developments and the potential of the global farmed fish market, estimated to exceed $306 billion, underscoring the economic and environmental significance of this research.